Overview

A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate the efficacy and safety of KRX-0502, administered without food, in treating iron deficiency anemia in subjects with stage 3 to 5 non-dialysis dependent chronic kidney disease (NDD-CKD).
Phase:
Phase 2
Details
Lead Sponsor:
Keryx Biopharmaceuticals
Treatments:
Citric Acid